Clearmind Medicine Inc. has filed a European patent application for novel psychedelic compounds aimed at treating PTSD and other mental health disorders. This move strengthens Clearmind's intellectual property in Europe and aligns with recent U.S. policy encouraging psychedelic therapy research. The global PTSD treatment market is expected to grow to $30.2 billion by 2035, highlighting the commercial potential. Clearmind holds exclusive global rights to develop and commercialize these compounds under a licensing deal with Yissum Research Development Company.
Wedbush analyst Dan Ives praised SpaceX's IPO as a 'Goldilocks outcome' that reassures investors and supports the tech sector. The successful debut, with shares closing 19.3% above the IPO price, signals strong investor interest and paves the way for...
Royal Unibrew increased its share buy-back program from DKK 400 million to DKK 700 million, repurchasing a total of 1,067,000 shares at an average price of DKK 458.58. The program, initiated on February 26, 2026, will run until August 14, 2026, with ...
IREN Limited has completed the acquisition of Nostrum Group, a Spanish developer of grid-connected AI data centers, marking IREN's entry into the European market. This deal adds about 490MW of secured power capacity and a development pipeline in Spai...
Red Cat Holdings shares increased by 4.83% in premarket trading following the launch of Hellcat, a new small unmanned aircraft system designed for versatile mission needs. Built on a modular platform, Hellcat supports customizable command, payloads, ...
Skanska has secured a SEK 4.4 billion contract to construct a new emergency hospital building at Karlstad Central Hospital in Sweden. The high-tech, seven-story building will cover approximately 90,000 square meters and include an emergency departmen...
